Identification

Name
Terbutaline
Accession Number
DB00871  (APRD00589)
Type
Small Molecule
Groups
Approved
Description

A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [PubChem]

Structure
Thumb
Synonyms
  • Terbutalin
  • Terbutalina
  • Terbutaline (sulfate de)
  • Terbutalini sulfas
  • Terbutalinsulfat
  • Terbutalinum
External IDs
KWD 2019
Product Ingredients
IngredientUNIICASInChI Key
Terbutaline Sulfate576PU70Y8E23031-32-5MUPQZWGSBCWCAV-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bricanyl Tab 2.5 mgTablet2.5 mgOralAstra Zeneca1978-12-312000-07-20Canada
Bricanyl Tab 5 mgTablet5 mgOralAstra Zeneca1975-12-312001-07-23Canada
Bricanyl TurbuhalerPowder, metered0.5 mgRespiratory (inhalation)Astra Zeneca1990-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Terbutaline SulfateInjection, solution1 mg/mLSubcutaneousGeneral Injectables & Vaccines2011-11-16Not applicableUs
Terbutaline SulfateInjection1 mg/mLSubcutaneousWest Ward Pharmaceutical2009-05-20Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralRebel Distributors2005-03-25Not applicableUs
Terbutaline SulfateInjection1 mg/mLSubcutaneousUnited Biomedical Inc., Asia2014-12-15Not applicableUs
Terbutaline SulfateTablet5 mg/1OralAmerincan Health Packaging2008-03-122016-01-01Us
Terbutaline SulfateTablet2.5 mg/1OralLannett Company, Inc.2005-03-25Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralAv Kare, Inc.2001-06-262015-12-29Us
Terbutaline SulfateInjection1 mg/mLSubcutaneousMedical Purchasing Solutions. Llc2009-05-20Not applicableUs
Terbutaline SulfateTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2005-03-25Not applicableUs00527 1311 01 nlmimage10 2d2696b4
International/Other Brands
Brethaire (Novartis) / Brethine / Bricanyl (AstraZeneca) / Bricardyl (Johnson) / Bricasma (AstraZeneca) / Bricasol (AstraZeneca) / Dracanyl (AstraZeneca) / Terbasmin (AstraZeneca)
Categories
UNII
N8ONU3L3PG
CAS number
23031-25-6
Weight
Average: 225.2842
Monoisotopic: 225.136493479
Chemical Formula
C12H19NO3
InChI Key
XWTYSIMOBUGWOL-UHFFFAOYSA-N
InChI
InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
IUPAC Name
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
SMILES
CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1

Pharmacology

Indication

For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.

Associated Conditions
Pharmacodynamics

Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation.

Mechanism of action

The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

TargetActionsOrganism
ABeta-2 adrenergic receptor
agonist
Human
UBeta-3 adrenergic receptor
agonist
Human
UBeta-1 adrenergic receptor
antagonist
Human
Absorption

Approximately 30-50% if administered orally and well absorbed subcutaneously.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. It appears that the sulfate conjugate is a major metabolite of terbutaline and urinary excretion is the primary route of elimination

Half life

5.5-5.9 hours

Clearance
  • 311 +/- 112 mL/min
Toxicity

Terbutaline Sulfate: Oral LD50(rat) = 8.7 g/kg; Oral LD50(mouse) = 205 mg/kg; Oral LD50(dog) = 1.5 g/kg; IP LD50(rat)= 220 mg/kg ; IP LD50(mouse) = 130 mg/kg; Oral LD50(rabbit) = >8 g/kg; IV LD50(mouse) = 36 mg/kg; IV LD50(dog) = 116 mg/kg; IV LD50(rabbit) = 110 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Terbutaline.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Terbutaline.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Terbutaline.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Terbutaline is combined with Acebutolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Terbutaline.Approved, Experimental, Investigational
AcepromazineTerbutaline may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Terbutaline.Approved
AcetohexamideTerbutaline may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Acetylcholine.Approved
AcetyldigitoxinTerbutaline may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinTerbutaline may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Terbutaline.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Experimental, Investigational
AlaproclateThe serum concentration of Terbutaline can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Terbutaline.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Terbutaline.Approved, Illicit
AlfuzosinTerbutaline may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Terbutaline.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Terbutaline.Experimental
AlprenololAlprenolol may decrease the bronchodilatory activities of Terbutaline.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Terbutaline.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Terbutaline.Illicit, Withdrawn
AmiodaroneThe therapeutic efficacy of Terbutaline can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Terbutaline.Vet Approved
AmitriptylineTerbutaline may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Terbutaline.Approved, Investigational
AmobarbitalThe serum concentration of Terbutaline can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Terbutaline can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Terbutaline.Approved, Illicit, Investigational
AnagrelideTerbutaline may increase the QTc-prolonging activities of Anagrelide.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Terbutaline.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Terbutaline.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Terbutaline.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Arecoline.Experimental
AripiprazoleTerbutaline may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
Arsenic trioxideTerbutaline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTerbutaline may increase the QTc-prolonging activities of Artemether.Approved
AsenapineTerbutaline may increase the QTc-prolonging activities of Asenapine.Approved
AtenololAtenolol may decrease the bronchodilatory activities of Terbutaline.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Terbutaline.Approved
AtosibanThe risk or severity of adverse effects can be increased when Terbutaline is combined with Atosiban.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Terbutaline.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Terbutaline.Approved
AzithromycinTerbutaline may increase the QTc-prolonging activities of Azithromycin.Approved
AzosemideTerbutaline may increase the hypokalemic activities of Azosemide.Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
BarbexacloneThe serum concentration of Terbutaline can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Terbutaline can be decreased when it is combined with Barbital.Illicit
BedaquilineTerbutaline may increase the QTc-prolonging activities of Bedaquiline.Approved
BendazacBendazac may decrease the antihypertensive activities of Terbutaline.Experimental
BendroflumethiazideTerbutaline may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Terbutaline.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Terbutaline.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Terbutaline.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Illicit
BenzthiazideTerbutaline may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineBenzydamine may decrease the antihypertensive activities of Terbutaline.Approved
Benzylpenicilloyl PolylysineTerbutaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Betahistine.Approved, Investigational
BetaxololBetaxolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Terbutaline is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
BevantololTerbutaline may increase the orthostatic hypotensive activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Terbutaline.Experimental
BisoprololBisoprolol may decrease the bronchodilatory activities of Terbutaline.Approved
BL-1020BL-1020 may increase the hypotensive activities of Terbutaline.Investigational
BopindololBopindolol may decrease the bronchodilatory activities of Terbutaline.Approved
BrexpiprazoleTerbutaline may increase the orthostatic hypotensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Terbutaline.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Terbutaline.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Terbutaline.Investigational
BucindololTerbutaline may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Terbutaline.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Terbutaline.Experimental
BumetanideTerbutaline may increase the hypokalemic activities of Bumetanide.Approved
BunazosinTerbutaline may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Terbutaline.Approved, Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Terbutaline.Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Terbutaline.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Terbutaline.Experimental, Investigational
CarbutamideTerbutaline may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Terbutaline.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved, Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Terbutaline.Approved
CarvedilolTerbutaline may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Terbutaline.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Terbutaline is combined with Celiprolol.Approved, Investigational
CeritinibTerbutaline may increase the QTc-prolonging activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Cevimeline.Approved
ChloroquineTerbutaline may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideTerbutaline may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Terbutaline.Experimental
ChlorpromazineTerbutaline may increase the orthostatic hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideTerbutaline may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneTerbutaline may increase the hypokalemic activities of Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Terbutaline.Approved
CiprofloxacinTerbutaline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTerbutaline may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramTerbutaline may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinTerbutaline may increase the QTc-prolonging activities of Clarithromycin.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Terbutaline.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
ClonixinClonixin may decrease the antihypertensive activities of Terbutaline.Approved
CloranololCloranolol may decrease the bronchodilatory activities of Terbutaline.Experimental
ClozapineTerbutaline may increase the orthostatic hypotensive activities of Clozapine.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Terbutaline.Vet Approved
CrizotinibTerbutaline may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
CyclopenthiazideTerbutaline may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CymarinTerbutaline may increase the bradycardic activities of Cymarin.Experimental
DapiprazoleTerbutaline may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Terbutaline can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Terbutaline.Approved
DemecariumDemecarium may increase the bradycardic activities of Terbutaline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.Approved, Investigational
DeslanosideTerbutaline may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Terbutaline.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Vet Approved
DextroamphetamineTerbutaline may increase the orthostatic hypotensive activities of Dextroamphetamine.Approved, Illicit
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Terbutaline.Experimental
DichlorvosDichlorvos may increase the bradycardic activities of Terbutaline.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Terbutaline.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
DigitoxinTerbutaline may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinTerbutaline may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Terbutaline may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Terbutaline.Approved, Investigational
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Terbutaline.Approved, Withdrawn
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Terbutaline.Approved
DistigmineDistigmine may increase the bradycardic activities of Terbutaline.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Terbutaline.Approved
DofetilideTerbutaline may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronTerbutaline may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneTerbutaline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Terbutaline.Approved
DopamineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Dopamine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Terbutaline.Approved
DoxazosinTerbutaline may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinTerbutaline may increase the orthostatic hypotensive activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Doxofylline is combined with Terbutaline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Terbutaline.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Terbutaline.Approved
DroperidolTerbutaline may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Terbutaline.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
DuloxetineDuloxetine may increase the tachycardic activities of Terbutaline.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Terbutaline.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Terbutaline.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Terbutaline.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Terbutaline.Approved
EliglustatTerbutaline may increase the QTc-prolonging activities of Eliglustat.Approved
EpanololThe risk or severity of adverse effects can be increased when Terbutaline is combined with Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Ephedrine.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Terbutaline.Approved
EpitizideTerbutaline may increase the hypokalemic activities of Epitizide.Experimental
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved
ErythromycinTerbutaline may increase the QTc-prolonging activities of Erythromycin.Approved, Investigational, Vet Approved
EscitalopramTerbutaline may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Terbutaline.Approved
Etacrynic acidTerbutaline may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Terbutaline.Experimental
EtilefrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Terbutaline.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
EtoperidoneThe serum concentration of Terbutaline can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Terbutaline.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Terbutaline.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Terbutaline.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Terbutaline.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Terbutaline.Approved
FenoterolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Terbutaline is combined with Fenozolone.Experimental
FentanylFentanyl may increase the bradycardic activities of Terbutaline.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Terbutaline.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Terbutaline.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Terbutaline.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Terbutaline.Experimental
FingolimodTerbutaline may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideTerbutaline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Terbutaline.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Terbutaline.Experimental
FluoxetineTerbutaline may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTerbutaline may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Terbutaline.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline.Approved, Investigational, Vet Approved
FurosemideTerbutaline may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Gadobenic acidTerbutaline may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Terbutaline.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Terbutaline.Approved
GemifloxacinTerbutaline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Terbutaline.Approved, Investigational, Nutraceutical
GitoformateTerbutaline may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideTerbutaline may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideTerbutaline may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTerbutaline may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTerbutaline may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneTerbutaline may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideTerbutaline may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideTerbutaline may increase the hypoglycemic activities of Glyburide.Approved
GoserelinTerbutaline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTerbutaline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Terbutaline is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Terbutaline.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
HaloperidolTerbutaline may increase the QTc-prolonging activities of Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Terbutaline.Experimental
HexobarbitalThe serum concentration of Terbutaline can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Terbutaline.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Terbutaline.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Terbutaline.Experimental
HydrochlorothiazideTerbutaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTerbutaline may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Hydroxyamphetamine.Approved
HydroxychloroquineThe metabolism of Terbutaline can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Terbutaline.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Terbutaline.Withdrawn
IbutilideTerbutaline may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
IloperidoneTerbutaline may increase the QTc-prolonging activities of Iloperidone.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Terbutaline.Experimental
ImipramineTerbutaline may increase the orthostatic hypotensive activities of Imipramine.Approved
IndalpineThe serum concentration of Terbutaline can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideTerbutaline may increase the hypokalemic activities of Indapamide.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Terbutaline.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Terbutaline.Withdrawn
IndoraminTerbutaline may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanTerbutaline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkTerbutaline may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Terbutaline.Approved, Investigational
IpidacrineIpidacrine may increase the bradycardic activities of Terbutaline.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Terbutaline.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Terbutaline.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Terbutaline.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Terbutaline.Approved, Investigational, Withdrawn
IsoprenalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Terbutaline.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Isoxsuprine.Approved, Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Terbutaline.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Terbutaline.Approved
LabetalolTerbutaline may increase the orthostatic hypotensive activities of Labetalol.Approved
Lanatoside CTerbutaline may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
LenvatinibTerbutaline may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LeuprolideTerbutaline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinTerbutaline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Terbutaline.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Terbutaline.Approved, Vet Approved
LinezolidLinezolid may increase the hypertensive activities of Terbutaline.Approved, Investigational
LisdexamfetamineTerbutaline may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Terbutaline.Investigational
LobelineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Lobeline.Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Terbutaline.Experimental
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Terbutaline.Experimental
LopinavirTerbutaline may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
LoxapineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Loxapine.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
LumefantrineTerbutaline may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Terbutaline.Approved
MalathionMalathion may increase the bradycardic activities of Terbutaline.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Terbutaline.Withdrawn
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Terbutaline.Approved
MefenorexThe risk or severity of adverse effects can be increased when Terbutaline is combined with Mefenorex.Experimental
MefloquineMefloquine may increase the bradycardic activities of Terbutaline.Approved, Investigational
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Terbutaline.Experimental, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Terbutaline.Approved, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Mephentermine.Approved
MepindololMepindolol may decrease the bronchodilatory activities of Terbutaline.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Terbutaline.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Terbutaline.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Terbutaline.Approved, Investigational
MetahexamideTerbutaline may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Terbutaline.Approved, Investigational, Withdrawn
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Terbutaline.Approved, Investigational
MethacholineTerbutaline may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethadoneTerbutaline may increase the QTc-prolonging activities of Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Terbutaline.Investigational
MethohexitalThe serum concentration of Terbutaline can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineTerbutaline may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Terbutaline.Approved, Investigational
MethyclothiazideTerbutaline may increase the hypokalemic activities of Methyclothiazide.Approved
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Terbutaline.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved
MethylphenobarbitalThe serum concentration of Terbutaline can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinTerbutaline may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Terbutaline.Approved, Investigational
MetolazoneTerbutaline may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
MidodrineTerbutaline may increase the bradycardic activities of Midodrine.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Terbutaline.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Terbutaline.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Terbutaline.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Terbutaline.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Terbutaline.Approved, Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Terbutaline.Experimental
MoricizineMoricizine may increase the hypotensive activities of Terbutaline.Approved, Investigational, Withdrawn
MoxifloxacinTerbutaline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Terbutaline.Approved
NabiloneNabilone may increase the tachycardic activities of Terbutaline.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Terbutaline.Approved
NadololNadolol may decrease the bronchodilatory activities of Terbutaline.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Terbutaline.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved
NebivololNebivolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
NefazodoneTerbutaline may increase the orthostatic hypotensive activities of Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Terbutaline.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Terbutaline.Withdrawn
NicardipineTerbutaline may increase the orthostatic hypotensive activities of Nicardipine.Approved, Investigational
NicergolineTerbutaline may increase the orthostatic hypotensive activities of Nicergoline.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Terbutaline.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Terbutaline.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Terbutaline.Approved
NiguldipineTerbutaline may increase the orthostatic hypotensive activities of Niguldipine.Experimental
NilotinibTerbutaline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Terbutaline.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Terbutaline.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
NortriptylineTerbutaline may increase the orthostatic hypotensive activities of Nortriptyline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Terbutaline is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Terbutaline.Withdrawn
OfloxacinTerbutaline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineTerbutaline may increase the orthostatic hypotensive activities of Olanzapine.Approved, Investigational
OleandrinTerbutaline may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Terbutaline.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Terbutaline.Approved
OndansetronTerbutaline may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Terbutaline.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Terbutaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Terbutaline.Vet Approved
OuabainTerbutaline may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Terbutaline.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Terbutaline.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Terbutaline.Approved, Withdrawn
PaliperidoneTerbutaline may increase the QTc-prolonging activities of Paliperidone.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Terbutaline.Experimental, Nutraceutical
PanobinostatTerbutaline may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Terbutaline.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Terbutaline.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline.Approved
ParoxetineThe serum concentration of Terbutaline can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
PazopanibTerbutaline may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
PentamidineTerbutaline may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentobarbitalThe serum concentration of Terbutaline can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerazinePerazine may increase the hypotensive activities of Terbutaline.Approved, Investigational
PerflutrenTerbutaline may increase the QTc-prolonging activities of Perflutren.Approved
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Terbutaline.Approved
PeruvosideTerbutaline may increase the bradycardic activities of Peruvoside.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Terbutaline.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Terbutaline.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Terbutaline.Approved, Illicit
PhenobarbitalThe serum concentration of Terbutaline can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineTerbutaline may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Terbutaline.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Terbutaline.Approved, Illicit
PhentolamineTerbutaline may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Terbutaline.Approved, Vet Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Terbutaline.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Terbutaline.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Terbutaline.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
PimozideTerbutaline may increase the QTc-prolonging activities of Pimozide.Approved
PindololPindolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
PiretanideTerbutaline may increase the hypokalemic activities of Piretanide.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Terbutaline.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Terbutaline.Experimental
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Terbutaline.Withdrawn
PizotifenTerbutaline may increase the orthostatic hypotensive activities of Pizotifen.Approved
PolythiazideTerbutaline may increase the hypokalemic activities of Polythiazide.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Terbutaline.Experimental, Investigational
PrazosinTerbutaline may increase the orthostatic hypotensive activities of Prazosin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Prenalterol.Experimental
PrimaquineTerbutaline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Terbutaline can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideTerbutaline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Terbutaline.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Terbutaline.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Terbutaline.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Terbutaline.Experimental
PromazineTerbutaline may increase the orthostatic hypotensive activities of Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Terbutaline.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
PropafenoneThe serum concentration of Terbutaline can be increased when it is combined with Propafenone.Approved
PropericiazineTerbutaline may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazineTerbutaline may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Terbutaline.Vet Approved
PropiverineTerbutaline may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Terbutaline.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Terbutaline.Experimental
ProscillaridinTerbutaline may increase the bradycardic activities of Proscillaridin.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
PTC299PTC299 may decrease the antihypertensive activities of Terbutaline.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Terbutaline.Approved, Investigational
QuetiapineTerbutaline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneTerbutaline may increase the hypokalemic activities of Quinethazone.Approved
QuinidineTerbutaline may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineTerbutaline may increase the QTc-prolonging activities of Quinine.Approved
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Terbutaline.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Terbutaline.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Terbutaline.Approved
ReserpineReserpine may increase the hypotensive activities of Terbutaline.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Terbutaline.Approved, Experimental, Investigational
RifampicinThe serum concentration of Terbutaline can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Terbutaline can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Terbutaline can be decreased when it is combined with Rifaximin.Approved, Investigational
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline.Approved, Investigational
RivastigmineTerbutaline may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Terbutaline.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Terbutaline.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Terbutaline.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Terbutaline.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Terbutaline.Approved
SaquinavirTerbutaline may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SecobarbitalThe serum concentration of Terbutaline can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Terbutaline.Approved, Investigational, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Terbutaline.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Terbutaline.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Terbutaline.Investigational
SertralineThe serum concentration of Terbutaline can be increased when it is combined with Sertraline.Approved
SilodosinTerbutaline may increase the orthostatic hypotensive activities of Silodosin.Approved
SotalolSotalol may decrease the bronchodilatory activities of Terbutaline.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Terbutaline.Approved
SRT501SRT501 may decrease the antihypertensive activities of Terbutaline.Investigational
SufentanilSufentanil may increase the bradycardic activities of Terbutaline.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Terbutaline.Approved
SulfisoxazoleTerbutaline may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Terbutaline.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Terbutaline.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Terbutaline.Investigational, Withdrawn
TafenoquineThe metabolism of Terbutaline can be decreased when combined with Tafenoquine.Approved, Investigational
TamsulosinTerbutaline may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Terbutaline.Investigational
Tedizolid phosphateTedizolid Phosphate may increase the hypertensive activities of Terbutaline.Approved
TelavancinTerbutaline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTerbutaline may increase the QTc-prolonging activities of Telithromycin.Approved
TenidapTenidap may decrease the antihypertensive activities of Terbutaline.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Terbutaline.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Terbutaline.Vet Approved
TerazosinTerbutaline may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Terbutaline.Approved
TertatololTertatolol may decrease the bronchodilatory activities of Terbutaline.Experimental
TetrabenazineTerbutaline may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tetryzoline.Approved
ThiamylalThe serum concentration of Terbutaline can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Terbutaline.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Terbutaline.Withdrawn
ThiopentalThe serum concentration of Terbutaline can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineTerbutaline may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazineTerbutaline may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Terbutaline.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Terbutaline.Approved
TimololTimolol may decrease the bronchodilatory activities of Terbutaline.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Terbutaline.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
TolazamideTerbutaline may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTerbutaline may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideTerbutaline may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Terbutaline.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Terbutaline.Approved
TorasemideTerbutaline may increase the hypokalemic activities of Torasemide.Approved
ToremifeneTerbutaline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tramazoline.Investigational
TranilastTranilast may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.Approved, Investigational
TrazodoneTerbutaline may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tretoquinol.Experimental
TribenosideTribenoside may decrease the antihypertensive activities of Terbutaline.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Terbutaline.Vet Approved
TrichlormethiazideTerbutaline may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTerbutaline may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Terbutaline.Approved, Vet Approved
TrimazosinTerbutaline may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimipramineTerbutaline may increase the orthostatic hypotensive activities of Trimipramine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Terbutaline.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Terbutaline.Approved
TyramineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tyramine.Investigational, Nutraceutical
TyrothricinTyrothricin may increase the bradycardic activities of Terbutaline.Approved
UrapidilTerbutaline may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Terbutaline.Approved, Investigational, Withdrawn
VandetanibTerbutaline may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Varenicline.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Terbutaline.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Terbutaline.Approved
VerapamilTerbutaline may increase the orthostatic hypotensive activities of Verapamil.Approved
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Terbutaline.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Terbutaline.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Terbutaline can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneTerbutaline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Terbutaline.Withdrawn
ZuclopenthixolTerbutaline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Alison B. Lukacsko, Joseph J. Piala, "Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions." U.S. Patent US5260333, issued December, 1983.

US5260333
General References
  1. Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10. [PubMed:14610225]
  2. Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833]
  3. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329]
External Links
Human Metabolome Database
HMDB0015009
KEGG Compound
C07129
PubChem Compound
5403
PubChem Substance
46506887
ChemSpider
5210
BindingDB
25770
ChEBI
9449
ChEMBL
CHEMBL1760
Therapeutic Targets Database
DAP000246
PharmGKB
PA451616
IUPHAR
560
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Terbutaline
ATC Codes
R03CC53 — Terbutaline, combinationsR03CC03 — TerbutalineR03AC03 — Terbutaline
AHFS Codes
  • 12:12.08.12 — Selective Beta 2-adrenergic Agonists
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentExercised Induced Asthma1
2, 3TerminatedTreatmentExternal Cephalic Version1
3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Airways Disease / Chronic Obstructive Pulmonary Disease Exacerbation1
3CompletedTreatmentAsthma Bronchial3
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentStatus Asthmaticus1
4RecruitingTreatmentExternal Cephalic Version1
4Unknown StatusNot AvailableAsthma Bronchial1
4Unknown StatusTreatmentLabour Pain1
Not AvailableCompletedBasic ScienceSkeletal Muscle Fatigue in Humans1
Not AvailableCompletedTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedTreatmentFoetal distress syndrome1
Not AvailableCompletedTreatmentReproductive Techniques, Assisted1
Not AvailableNot Yet RecruitingBasic ScienceHypertrophy / Physical Activity / Physiologic Hypertrophy1
Not AvailableRecruitingBasic ScienceMuscle Hypertrophy in Healthy Young Men1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Sanofi aventis us llc
  • Aaipharma llc
  • Akorn inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hikma farmaceutica (portugal) sa
  • Teva parenteral medicines inc
  • Impax laboratories inc
  • Lannett holdings inc
Packagers
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • APP Pharmaceuticals
  • AstraZeneca Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cardinal Health
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Gallipot
  • Global Pharmaceuticals
  • Hikma Pharmaceuticals
  • Lannett Co. Inc.
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Rite Aid Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Tya Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral2.5 mg
TabletOral5 mg
Powder, meteredRespiratory (inhalation)0.5 mg
InjectionSubcutaneous1 mg/mL
Injection, solutionSubcutaneous1 mg/mL
TabletOral2.5 mg/1
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Terbutaline sulfate powder38.4USD g
Terbutaline Sulfate 1 mg/ml vial12.99USD vial
Terbutaline sulf 1 mg/ml vial4.8USD ml
Brethine 5 mg tablet0.83USD tablet
Terbutaline sulfate 5 mg tablet0.63USD tablet
Brethine 2.5 mg tablet0.57USD tablet
Terbutaline sulfate 2.5 mg tablet0.47USD tablet
Bricanyl Turbuhaler 0.5 mg/dose Metered Inhalation Powder0.08USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)119-122 °CNot Available
water solubility213 mg/mLNot Available
logP0.90TACAKS-NOVAK,K ET AL. (1995)
Caco2 permeability-6.38ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility5.84 mg/mLALOGPS
logP0.55ALOGPS
logP0.44ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)8.86ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity63.04 m3·mol-1ChemAxon
Polarizability24.78 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.987
Blood Brain Barrier-0.9355
Caco-2 permeable-0.8404
P-glycoprotein substrateSubstrate0.6335
P-glycoprotein inhibitor INon-inhibitor0.8954
P-glycoprotein inhibitor IINon-inhibitor0.9672
Renal organic cation transporterNon-inhibitor0.9067
CYP450 2C9 substrateNon-substrate0.7678
CYP450 2D6 substrateNon-substrate0.7922
CYP450 3A4 substrateNon-substrate0.6291
CYP450 1A2 substrateNon-inhibitor0.9516
CYP450 2C9 inhibitorNon-inhibitor0.9303
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9115
CYP450 3A4 inhibitorNon-inhibitor0.8766
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9117
Ames testNon AMES toxic0.9119
CarcinogenicityNon-carcinogens0.8484
BiodegradationNot ready biodegradable0.9808
Rat acute toxicity2.1080 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9548
hERG inhibition (predictor II)Non-inhibitor0.9467
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0290000000-8c26dbc913131cf49bc4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-3148282c5452a80b16c3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-9122151a6e70e6f2b536
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-0090000000-aab7f309385309d8884b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0920000000-1e85cd2bf4a0358c22d7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0900000000-82b70479a4e38921e06b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-2900000000-aff994ffd107ef3b6e71
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a6r-7900000000-cfe77aa0133facea1c75
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0udi-0900000000-1a0ccd393797b19105a0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0190000000-f9271bb736a512dbdbab
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-a70c8697ca7633839444
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a6r-1900000000-4a9c0ddb9af4ce93b4ae
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a6r-6900000000-0cc68c4a50196d6ffab6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-9400000000-e1cec349ffb2fcd3ebe2

Taxonomy

Description
This compound belongs to the class of organic compounds known as resorcinols. These are compounds containing a resorcinol moiety, which is a benzene ring bearing two hydroxyl groups at positions 1 and 3.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
Benzenediols
Direct Parent
Resorcinols
Alternative Parents
Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Monocyclic benzene moiety / 1,2-aminoalcohol / Secondary alcohol / Secondary amine / Secondary aliphatic amine / Aromatic alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenylethanolamines, resorcinols (CHEBI:9449)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Schafers RF, Piest U, von Birgelen C, Jakubetz J, Daul AE, Philipp T, Brodde OE: Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers. J Cardiovasc Pharmacol. 1999 May;33(5):822-7. [PubMed:10226872]
  2. Ramer-Quinn DS, Swanson MA, Lee WT, Sanders VM: Cytokine production by naive and primary effector CD4+ T cells exposed to norepinephrine. Brain Behav Immun. 2000 Dec;14(4):239-55. [PubMed:11120594]
  3. Zetterlund A, Hjemdahl P, Larsson K: beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. Clin Sci (Lond). 2001 Apr;100(4):451-7. [PubMed:11256987]
  4. Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T: Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription. J Am Soc Nephrol. 2001 Nov;12(11):2288-99. [PubMed:11675405]
  5. Chong LK, Suvarna K, Chess-Williams R, Peachell PT: Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol. 2003 Feb;138(3):512-20. [PubMed:12569076]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Riether C, Kavelaars A, Wirth T, Pacheco-Lopez G, Doenlen R, Willemen H, Heijnen CJ, Schedlowski M, Engler H: Stimulation of beta(2)-adrenergic receptors inhibits calcineurin activity in CD4(+) T cells via PKA-AKAP interaction. Brain Behav Immun. 2011 Jan;25(1):59-66. doi: 10.1016/j.bbi.2010.07.248. Epub 2010 Jul 30. [PubMed:20674738]
  8. Cooperberg BA, Breckenridge SM, Arbelaez AM, Cryer PE: Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2008 Dec;31(12):2271-2. doi: 10.2337/dc08-0520. Epub 2008 Sep 9. [PubMed:18782903]
  9. Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833]
  10. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]
  2. Behr B, Hoffmann C, Ottolina G, Klotz KN: Novel mutants of the human beta1-adrenergic receptor reveal amino acids relevant for receptor activation. J Biol Chem. 2006 Jun 30;281(26):18120-5. Epub 2006 Apr 28. [PubMed:16648137]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Kovarik Z, Simeon-Rudolf V: Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. J Enzyme Inhib Med Chem. 2004 Apr;19(2):113-7. [PubMed:15449725]

Drug created on June 13, 2005 07:24 / Updated on July 21, 2018 18:01